Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE

Chemical Biology and Drug Design

Volumn 83, Issue 1, 2014, Pages 81-88

  Niu, Mingshan ^a   Hu, Jin ^b   Wu, Sijin ^a   Zhang, Xiaoe ^a   Xu, Huaxi ^b   Zhang, Yunwu ^b   Zhang, Jie ^b   Yang, Yongliang ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

BACE1; drug repositioning; Gefitinib; structural bioinformatics

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; GEFITINIB;

ARTICLE; BINDING SITE; CELL VIABILITY; CONFORMATIONAL TRANSITION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STRUCTURAL BIOINFORMATICS;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891487225     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12200     Document Type: Article

References (25)

1. Goedert M., Spillantini M.G., (2006) A century of Alzheimer's disease. Science; 314: 777-781.
2. Hardy J., Allsop D., (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci; 12: 383-388.
3. Cole S.L., Vassar R., (2007) The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener; 2: 22.
4. Bennett B.D., Babu-Khan S., Loeloff R., Louis J.C., Curran E., Citron M., Vassar R,. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science; 286: 735-741.
5. Vassar R., (2004) BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci; 23: 105-114.
6. Karran E., Mercken M., De Strooper B., (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discovery; 10: 698-712.
7. Ghosh A.K., Brindisi M., Tang J., (2012) Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem; 120 (Suppl. 1): 71-83.
8. Brodney M.A., Barreiro G., Ogilvie K., Hajos-Korcsok E., Murray J., Vajdos F., Ambroise C., et al,. (2012) Spirocyclic sulfamides as beta-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors. J Med Chem; 55: 9224-9239.
9. Chong C.R., Sullivan D.J. Jr, (2007) New uses for old drugs. Nature; 448: 645-646.
10. Koul A., Arnoult E., Lounis N., Guillemont J., Andries K., (2011) The challenge of new drug discovery for tuberculosis. Nature; 469: 483-490.
11. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., et al,. (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science; 335: 1503-1506.
12. Hasinoff B.B., Wu X., Nitiss J.L., Kanagasabai R., Yalowich J.C., (2012) The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol; 84: 1617-1626.
13. Xie L., Evangelidis T., Bourne P.E., (2011) Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol; 7: e1002037.
14. Lang H., Huang X., Yang Y., (2012) Identification of putative molecular imaging probes for BACE-1 by accounting for protein flexibility in virtual screening. J Alzheimers Dis; 29: 351-359.
15. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E., (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem; 25: 1605-1612.
16. Xie L., Bourne P.E., (2011) Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol; 21: 189-199.
17. Zhang Y., Skolnick J., (2005) TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res; 33: 2302-2309.
18. Ren J., Xie L., Li W.W., Bourne P.E., (2010) SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic Acids Res; 38: W441-W444.
19. Greenfield J.P., Tsai J., Gouras G.K., Hai B., Thinakaran G., Checler F., Sisodia S.S., Greengard P., Xu H., (1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci USA; 96: 742-747.
20. Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., Nishizawa M., Ikeuchi T., (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry; 81: 608-610.
21. Huey R., Morris G.M., Olson A.J., Goodsell D.S., (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem; 28: 1145-1152.
22. Gruber C.C., Pleiss J., (2011) Systematic benchmarking of large molecular dynamics simulations employing GROMACS on massive multiprocessing facilities. J Comput Chem; 32: 600-606.
23. Sordella R., Bell D.W., Haber D.A., Settleman J., (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science; 305: 1163-1167.
24. Xie L., Bourne P.E., (2009) A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics; 25: i305-i312.
25. Wang L., Chiang H.C., Wu W., Liang B., Xie Z., Yao X., Ma W., Du S., Zhong Y., (2012) Epidermal growth factor receptor is a preferred target for treating amyloid-beta-induced memory loss. Proc Natl Acad Sci USA; 109: 16743-16748.